Medivir announces the first cancer project derived from its in-house nucleotide platform


Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a new
discovery project for a cancer indication, a liver targeted nucleotide prodrug
for the treatment of hepatocellular carcinoma (HCC). The project is based on the
company’s expertise in nucleoside and nucleotide science and is the first cancer
project to emerge from its in-house discovery efforts in oncology that were
announced in 2014.

“Our HCC nucleotide project has made very rapid progress after its initiation
last year” said Richard Bethell, EVP Discovery Research. “We have identified
molecules with excellent activity against a range of HCC cell lines and with the
required distribution properties to enable them to be delivered selectively to
the liver. Preclinical testing of these molecules in relevant models of HCC will
begin early in the third quarter.”

Hepatocellular carcinoma is the most common cancer of the liver. Liver cancer is
the second leading cause of cancer-related death world-wide, and one of the
fastest growing cancers in the US based on incidence and mortality.

For further information, please contact:
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Richard Bethell, EVP Discovery Research Medivir AB, mobile: +46 (0) 727 043 211

Medivir is required under the Securities Markets Act to make the information in
this press release public.
The information was submitted for publication at 08.30 CET on 30 June 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on
infectious diseases and oncology. We have a leading competence within protease
inhibitor design and nucleotide/nucleoside science and we are dedicated to
develop innovative pharmaceuticals that meet great unmet medical need. Our
commercial organization provides a growing portfolio of specialty care
pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm
Mid Cap List.

Attachments

06308029.pdf